MAIA Biotechnology awarded $2.3M NIH grant for THIO-101 Phase 2 trial in NSCLC

MAIA Biotechnology, Inc.

NIH grant of $2.3M supports expansion of THIO-101 Phase 2 trial evaluating ateganosine as third-line NSCLC treatment.
Grant funds enrollment of US patients resistant to chemo/immunotherapy; distributed over 3 years (2025-2027).
First US patient enrollment to begin immediately following 2023 FDA IND clearance; first expansion patient dosed July 2025 in Taiwan.
Median overall survival for 22 third-line patients was 17.8 months (June 30, 2025) vs 5-6 months for standard chemo.
Grant is non-dilutive funding from NIH's National Cancer Institute (Award R44CA309843).

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.